Advances in Cell and Gene Therapy are creating a new revolution in medicine. Early pioneers have advanced our ability to program and modify genes. They have made substantial and dramatic progress, but most of what we can deliver is yet to come.

GeneTether has developed a proprietary method to conjugate, or “tether,” donor DNA templates to CRISPR/Cas9 and other nucleases. We refer to this as our DNA Template-Nuclease-Tethering, or TNT™, Platform.

Our Co-Founders

GeneTether’s leadership consists of senior individuals with strong track records in building life sciences companies at all stages of growth.

Har Grover, BSc, MBA, ICD.D

Chief Executive Officer & Board Member

Mr. Grover is an entrepreneur, investor, senior executive and strategist with over 30 years of experience in healthcare, life sciences and technology. He has worked with growth companies at all stages, from start-up to commercialization, to going public and growing through the $1 billion revenue mark. He has helped companies enter new markets both in Canada and internationally – organically and through M&A, strategic alliances, and joint ventures. Mr. Grover is presently the CEO of GeneTether Inc. He was previously Chairman and CEO of Scientus Pharma, Co-Founder and CEO of CannScience Innovations, as well as Founder and Managing Director of Nucleus GC. He has served on several corporate and non-profit boards, including Chair of Armour Therapeutics, Chair of Crohn’s and Colitis Canada, Board Director of Medworxx, and Board Director of MedcannAccess. Har has an undergraduate degree in life sciences, an MBA, and has obtained professional CMC and ICD.D designations.


R. Geoffrey Sargent, PhD

Chief Scientific Officer & Board Member

Dr. Sargent has been working in the field of gene editing in mammalian cells since 1987, beginning with his postdoctoral studies at the Imperial Cancer Research Fund (now Cancer Research UK) and Baylor College of Medicine. Dr. Sargent has worked in the Bay Area since 1998, directing academic and biotech company research programs focused on developing high efficiency gene editing technologies for human therapeutics and agricultural applications as well as human pluripotent stem cell applications. He teaches Biochemistry and Stem Cell Biology courses at UC Berkeley Extension and was previously a research scientist at UC San Francisco. Dr. Sargent earned his undergraduate degree in Applied Biology at Georgia Institute of Technology and his PhD in Biochemistry and Biophysics at Oregon State University.


William J. Garner, MD, MPH

Board Member

Dr. Garner is a physician, investor and entrepreneur who has founded and co-founded numerous life science companies, including Race Oncology, Tryp Therapeutics, and Isla Pharmaceuticals, among others. In addition to serving as Founder and Managing Director of EGB Ventures, Dr. Garner has served in management roles and on the boards of a number of EGB Ventures portfolio companies. Prior to EGB, Dr. Garner held positions in the medical affairs division of Hoffmann LaRoche – Oncology and at a merchant banking firm in New York City. Dr. Garner earned his MD from New York Medical College and a Masters of Public Health from the Harvard T.H. Chan School of Public Health. He trained in the Anatomic Pathology residency program at Columbia-Presbyterian and is currently a licensed physician in the State of New York.


Daren Graham, BBA, JD

Chairman 

Mr. Graham has nearly 20 years of experience in the life science industry as a merchant banker, senior operations executive, and corporate finance attorney. He is currently Chief Operating Officer of EGB Ventures. Previously he was a Co-Founder of Osteon Therapeutics, Managing Director of Allele Capital Partners, Executive Director in Tribal Capital Markets’ Equity Capital Life Sciences Division, and Chief Legal Officer and Vice President of Strategic Development at Sancilio Pharmaceuticals Company. Mr. Graham began his career as a corporate finance attorney in the Boston headquarters of Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo PC, representing both private and public life science companies in private and public financings. After receiving a BBA in Finance from Northeastern State University of Oklahoma, Mr. Graham earned his Juris Doctorate from Boston College Law School. He is a member of the Massachusetts Bar and holds FINRA Series 7, 63 and 79 licenses.